A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fundació Sant Joan de Déu
Milton S. Hershey Medical Center
University of Cologne
Fundació Sant Joan de Déu
Memorial Sloan Kettering Cancer Center
Laboratorio Elea Phoenix S.A.
Children's Hospital Los Angeles
University of Iowa
National Cancer Institute (NCI)
New Approaches to Neuroblastoma Therapy Consortium
Children's Oncology Group
University of Iowa
University of Iowa
University of Regensburg
Children's Oncology Group
Baylor College of Medicine
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Samsung Medical Center
University of Michigan Rogel Cancer Center
Molecular Insight Pharmaceuticals, Inc.
Children's Oncology Group
Fred Hutchinson Cancer Center
Samsung Medical Center
Centre Oscar Lambret
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Children's Oncology Group
University of California, San Francisco
Children's Oncology Group
Children's Oncology Group